In this report we demonstrate the criteria required to ensure a successful home treatment programme and describe our experience thus far” Finnigan et al (2017).
Abstract:
Enzyme replacement therapy is the only available treatment for Mucopolysaccharidosis type IVA (MPS IVA, Morquio syndrome). The treatment is lengthy and invasive involving weekly intravenous infusions of 4-5 h. This can cause significant disruption to normal family life so the provision of a safe and effective homecare service is essential. In order to deliver a safe service, robust standards must be in place; this includes appropriately trained members of homecare staff, detailed management for infusion related reactions (IRR) and appropriate venous access. In this report we demonstrate the criteria required to ensure a successful home treatment programme and describe our experience thus far.
[ctt link=”Yl61a” template=”1″]ReTweet if useful… Home infusion with Elosulfase alpha in a UK paediatric setting https://ctt.ec/Yl61a+ @ivteam #ivteam[/ctt]
Reference:
Finnigan, N., Roberts, J., Mercer, J. and Jones, S.A. (2017) Home infusion with Elosulfase alpha (VimizimR) in a UK Paediatric setting. Molecular Genetics and Metabolism Reports. 14, p.15-18. eCollection.
doi: 10.1016/j.ymgmr.2017.10.012.
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]